Thus, Survivin compartmentalization appears to be an important predictive biomarker for alkylation drug-based glioblastoma therapy and manipulating Survivin subcellular localization towards permanent trapping in the nucleus would facilitate TMZ response of malignant gliomas. Here, BIRC5 is linked to glioblastoma.